Eye Scan + Blood Test Help Spot MS Who May Worsen

Credibility

Interest

Share:2 min read

Key Takeaway

Combining a blood test for sGFAP (a sign of brain cell stress) and a simple eye scan helps predict which people with MS are more likely to get worse over time.

What They Found

Researchers compared a blood protein called sGFAP, which rises when certain brain support cells (astrocytes) are stressed, with eye scans that measure nerve cell layers in the retina. People with MS who had higher sGFAP levels tended to have thinner retinal nerve layers, suggesting both signs point to more nerve damage. Over about three years, people with both high sGFAP and thin retinal layers got worse faster on a common disability scale than those with one or neither sign. Having just one bad sign (either high sGFAP or thin retina) still meant a faster decline than having good results on both tests. These two measures together gave a clearer picture of who is at higher risk for disability than either test alone, like using both a warning light and a temperature gauge to judge a car problem.

Who Should Care and Why

People with MS and their caregivers should care because these tests could help spot higher risk for future disability earlier, which might change monitoring or treatment choices. Doctors could use the blood test and eye scan together to decide if someone needs closer follow-up, more aggressive therapy, or extra support services. The eye scan is quick and painless, like taking a photo of the back of the eye, and the blood test is a routine blood draw—both are easy to add to clinic visits. If you know you are in a higher-risk group, you can plan for things like physical therapy, mobility aids, or changes in work or daily routines sooner. This information may help families and care teams make practical plans, similar to preparing an umbrella if a weather forecast shows a higher chance of rain.

Important Considerations

This study followed people for about three years, so it shows short- to mid-term trends but not long-term outcomes beyond that time. The findings show association (a link) but do not prove that high sGFAP or thin retinal layers directly cause disability; other factors could be involved. Results may not apply to every person with MS because the study group had specific characteristics (age, treatments) and more research is needed before these tests become standard care.

AI-generated summary — for informational purposes only, not medical advice

Categories:

MS Diagnostics MS Progression Early Research

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Neurology(R) neuroimmunology & neuroinflammation often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News